Search Results 541-550 of 12469 for alp

  1. Alcoholic hepatitis (Alcohol-associated hepatitis) - Symptoms and causes - Mayo Clinic

    Alcoholic hepatitis is a type of liver damage and swelling caused by drinking alcohol. This swelling, called inflammation, damages liver cells.

  2. A Study to Establish a Registry for the Pulmonary Hypertension Association - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  3. Antiphospholipid syndrome - Doctors and departments - Mayo Clinic

    Learn about causes and treatment of this blood disorder that mainly affects women and may cause blood clots and miscarriages.

  4. A Study to Evaluate the Effectiveness and Safety of Vedolizumab to Treat Chronic Pouchitis - Mayo Clinic

    Alkaline phosphatase > 3 × ULN;; Serum creatinine > 2 × ULN. Has chronic hepatitis B virus (HBV) infection* or chronic hepatitis C virus (HCV) infection** or ...

  5. Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps - Mayo Clinic

    Alkaline phosphatase =< 1.5 x institutional upper limit of normal; Total bilirubin =< 1.5 x institutional upper limit of normal; Blood urea nitrogen (BUN) ...

  6. Spinal fusion - Doctors & Departments - Mayo Clinic

    This procedure connects two or more bones in the spine. The bones then can't move, which helps ease neck or back pain.

  7. Medical Research & Education - Mayo Clinic News Network

    Mayo Clinic deploys NVIDIA Blackwell infrastructure to drive generative AI solutions in medicine. ROCHESTER, Minn. — Mayo Clinic took a pivotal step toward ...

  8. Letrozole After Tamoxifen in Treating Women With Breast Cancer - Mayo Clinic

    Alkaline phosphatase < 2 times ULN (unless imaging examinations have ruled out metastatic disease). Renal: Not specified; Other: No concurrent medical or ...

  9. Study Is To Assess The Safety And Tolerability Of VTx-002 In Participants With ALS - Mayo Clinic

    PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects ...

  10. A Study of 9-ING-41 in Patients with Advanced Cancers - Mayo Clinic

    aminotransferase, AST/ALT) and alkaline phosphatase ≤ 3 (≤ 5 X the upper limit of normal (ULN) in the setting of liver metastasis or infiltration with ...